Capricor Therapeutics Faces Investor Class Action Lawsuit Amid Allegations of Misleading Data

Investor Deadline Alert: Capricor Therapeutics Class Action

Overview of the Lawsuit

Capricor Therapeutics, Inc., publicly traded on NASDAQ under the ticker CAPR, is currently facing a class action lawsuit linked to allegations of securities fraud. Hagens Berman, a law firm specializing in representing shareholders, is urging investors who experienced substantial losses during the company’s operations between December 17, 2025, and July 26, 2026, to come forth and have their voices heard. This lawsuit provides those affected a chance to recover some of their potential losses and possibly assume the role of lead plaintiff in court proceedings.

Key Allegations Against Capricor

The core of the lawsuit revolves around accusations that Capricor and some of its executives issued materially false and misleading statements. These statements pertained to the clinical trial outcomes and the regulatory pathway concerning the firm's lead product candidate, Deramiocel, previously aimed at treating Duchenne Muscular Dystrophy (DMD). Notably, it is asserted that the defendants did not disclose they had modified the pre-specified statistical analysis plan (SAP) without prior FDA agreement before resubmitting their Biologics License Application (BLA).

The HOPE-3 Study Announcement

On December 3, 2025, Capricor announced what it termed “Positive Topline Results” from its pivotal Phase 3 HOPE-3 study involving Deramiocel. The company's CEO was quoted claiming robust and definitive evidence that the drug significantly improved DMD outcomes, which led to Capricor shares soaring by an astonishing 370%. Following this, the company sought to conduct a public offering of approximately six million shares at $25 each.

Stock Price Collapse Following FDA Briefing

However, troubles emerged on July 27, 2026, when the FDA released a briefing document ahead of the upcoming meeting regarding Capricor's BLA. The document highlighted critical flaws in the data from the HOPE-3 study, stating that the trial did not meet its specified primary and secondary endpoints intended to showcase the efficacy of Deramiocel. This disclosure triggered a dramatic plunge in share prices, with Capricor’s stock collapsing by roughly 64%, settling at $7.

Legal Action for Affected Investors

Investors who acquired Capricor securities within the specified timeframe and incurred considerable losses now have until September 28, 2026, to express their interest in being designated as lead plaintiffs. Although individuals do not need to be in this role to be eligible for potential recoveries, it is important to act swiftly.

Hagens Berman offers various avenues for investors seeking to understand their legal options: they can visit Hagens Berman's website, reach out via phone at 844-916-0895, or send inquiries via email.

Whistleblower Opportunities

For those possessing non-public information regarding Capricor, avenues are available to assist in the case or participate in the SEC Whistleblower program. The initiative offers monetary compensation to whistleblowers who reveal original insights that help in significant recoveries made by the SEC.

Conclusion

As the legal battle unfolds, Capricor Therapeutics' current investors must remain vigilant. The Hagens Berman firm's focus is to uncover the extensive details surrounding these misleading representations and ultimately ensure accountability for the management's actions during the clinical trial assessments.

For further information on the investigation or to receive updates, stakeholders are encouraged to follow Hagens Berman’s initiatives online at @ClassActionLaw.